Clinical features and oncological outcomes of primary female urethral cancer

Lee, Won‐Chul; Yu, Jihion; Lee, Jae‐Lyun; Kim, Young Seok; Hong, Bumsik

doi:10.1002/jso.26790

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the primary urethral carcinoma, its long-term survival after surgery is mainly referenced from the RARECARE (The project Surveillance of Rare Cancers in Europe) project [ 28 ] and the large SEER database [ 13 ] and results often cover early period. Certain recent studies also have reported differences in survival outcomes among different clinical stages and treatment modalities [ 29 , 30 , 31 , 32 ]. The prognostic outcome is determined largely by the clinical stage and pathological grade, distant metastasis presence and nodal stage, as well as type and modality of treatment [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Management of Primary Female Urethral Adenocarcinoma: Two Rare Case Reports and Literature Review

Tian

Tao

et al. 2023

Medicina

View full text Add to dashboard Cite

Primary urethral adenocarcinoma in females is an extremely rare malignancy with unclear origin and only a few retrospective cases have been reported. The controversy continues to exist over the origin of primary urethral adenocarcinoma from periurethral glands (which include the Skene’s glands), urethritis glandularis or intestinal metaplasia. Herein, we report one case of a 49-year-old female with distal urethral adenocarcinoma who presented with obstructive voiding. Abdominal and pelvic CT scans and chest radiology were unremarkable. Biopsy of the mass confirmed urethral adenocarcinoma. The patient underwent partial ureterectomy and was disease-free at the 2-years follow-up period. We also present another extremely rare case of primary urethral adenocarcinoma with mucinous features in a 58-year-old female who initially complained of external urethral orifice itching with painless urethral bleeding and was treated with local excision. The patient has not received any neoadjuvant or adjuvant therapy, and experienced tumor recurrence, inguinal lymph nodes metastasis, and even local iliopsoas metastasis during over 10-years follow-up. In conclusion, our current study emphasizes the importance of imaging studies and biopsy in making an accurate preoperative diagnosis of this rare disease, and further highlights the role of multimodal therapy. A combination of radiotherapy, chemotherapy and surgery is recommended for the optimal local and distant disease control. Moreover, better medical compliance and regular follow-up are required in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of Primary Female Urethral Adenocarcinoma: Two Rare Case Reports and Literature Review

Tian

Tao

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…Due to the low incidence of PUCs, no statistics on survival of metastatic PUCs are available. Metastatic PUC lacks optimal treatment strategies based on current study data, chemotherapy is the main treatment, and multi-mode therapy is recommended ( 10 , 11 ). The efficacy of various therapeutic strategies, including immunotherapy and targeted therapy, has only been reported in a few individual cases.…”

Section: Introductionmentioning

confidence: 99%

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report

Zheng,

Xue,

Zhao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low HER2 expression that developed disease progression after multiline therapy including chemotherapy, programmed death-1 (PD-1) inhibitors and multi-targeted receptor tyrosine kinase (RTK) inhibitor. After receiving Disitamab Vedotin(a novel antibody drug conjugate, ADC) and toripalimab (a PD-1 inhibitor), the patient achieved persistent PR, and the PFS exceeded 12 months up to now. Our report indicates that, despite the patient of metastatic PUC has low expression of HER2, it is still possible to benefit from Disitamab Vedotin combined with PD-1 inhibitor, which may reverse the drug resistance of PD-1 inhibitor and chemotherapy to a certain extent. But larger sample studies are needed to determine the efficacy of this treatment strategy and its impact on survival.

show abstract

Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors

Han,

Meng,

Jianguo

2024

CCDT

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) offer significant advantages for the treatment of urologic tumors, enhancing the immune function of anti-tumor T cells by inhibiting PD-1 and PDL1 binding. They have been shown to be well tolerated and remarkably effective in clinical practice, offering hope to many patients who are not well treated with conventional drugs. Clinical trials in recent years have shown that anti-PD-1 and PD-L1 antibodies have good efficacy and safety in the treatment of urologic tumors. These antibodies can be applied to a variety of urologic tumors, such as bladder cancer, renal cell carcinoma, and prostate cancer. They have been approved for the first-line treatment or as an option for follow-up therapy. By blocking the PD-1/PD-L1 signaling pathway, ICIs can release immune functions that are suppressed by tumor cells and enhance T-cell killing, thereby inhibiting tumor growth and metastasis. This therapeutic approach has achieved encouraging efficacy and improved survival for many patients. Although ICIs have shown remarkable results in the treatment of urologic tumors, some problems remain, such as drug resistance and adverse effects in some patients. Therefore, further studies remain important to optimize treatment strategies and improve clinical response in patients. In conclusion, PD-1/PD-L1 signaling pathway blockers have important research advances for the treatment of urologic tumors. Their emergence brings new hope for patients who have poor outcomes with traditional drug therapy and provides new options for immunotherapy of urologic tumors. The purpose of this article is to review the research progress of PD-1 and PD-L1 signaling pathway blockers in urologic tumors in recent years.

show abstract

Clinical features and oncological outcomes of primary female urethral cancer

Cited by 3 publications

References 27 publications

Management of Primary Female Urethral Adenocarcinoma: Two Rare Case Reports and Literature Review

Management of Primary Female Urethral Adenocarcinoma: Two Rare Case Reports and Literature Review

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report

Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors

Contact Info

Product

Resources

About